Imatinib for refractory chronic graft-versus-host disease with fibrotic features. - Wikidata - awgldk - TriplyDB

Imatinib for refractory chronic graft-versus-host disease with fibrotic features.

Imatinib for refractory chronic graft-versus-host disease with fibrotic features.

http://www.wikidata.org/entity/Q46031486

about

Treatment of chronic graft-versus-host disease in 2011 Graft-versus-host disease: why have we not made more progress?Fibrotic and sclerotic manifestations of chronic graft-versus-host disease The Role of Animal Models in the Study of Hematopoietic Stem Cell Transplantation and GvHD: A Historical Overview Chronic graft-versus-host disease (GVHD) in children.Advances in graft-versus-host disease biology and therapy.Pathogenesis and management of graft-versus-host disease.Organ-specific management and supportive care in chronic graft-versus-host disease.CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease.Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia Treatment of chronic graft-versus-host disease: Past, present and future.Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease.Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.How I treat childhood CML.A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies.Clinical benefit of response in chronic graft-versus-host disease A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation.Antibodies from donor B cells perpetuate cutaneous chronic graft-versus-host disease in mice.Interleukin-2 and regulatory T cells in graft-versus-host disease.Imatinib and dasatinib as salvage therapy for sclerotic chronic graft-vs-host disease Profibrotic TGFβ responses require the cooperative action of PDGF and ErbB receptor tyrosine kinases.Agonistic Anti-PDGF Receptor Autoantibodies from Patients with Systemic Sclerosis Impact Human Pulmonary Artery Smooth Muscle Cells Function In Vitro.The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant.Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors.Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD.German-Austrian-Swiss Consensus Conference on clinical practice in chronic graft-versus-host disease (GVHD): guidance for supportive therapy of chronic cutaneous and musculoskeletal GVHD.Bronchiolitis obliterans after allo-SCT: clinical criteria and treatment options.More than skin deep? Emerging therapies for chronic cutaneous GVHD.Low-dose imatinib in the treatment of severe systemic sclerosis: a case series of six Chinese patients and literature review.Therapeutic benefits targeting B-cells in chronic graft-versus-host disease.State-of-the-art acute and chronic GVHD treatment.Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence.Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: The Difficulty in Interpreting Proof-of-Concept Studies.Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party o Classification systems for chronic graft-versus-host disease.Acute and chronic Graft-versus-host disease after hematopoietic stem cell transplantation.Bronchiolitis obliterans syndrome in adults after allogeneic stem cell transplantation-pathophysiology, diagnostics and treatment.The scientific basis for novel treatments of systemic sclerosis.

P2860

Q26851433-FEB9FB60-82B1-4DE8-A996-E11786221759 Q27012940-D639DFD7-B0C7-4A65-8AE3-10C2BF67332F Q27024147-FD9C2187-671D-4F24-830D-178704B93B84 Q28066083-3A171734-E820-420F-ABA6-CF646DC91F9F Q33857680-6F3CFD17-8502-4CBC-B24A-175D178157B2 Q34031916-9E3ED3A3-6612-450F-AFEC-47728377477C Q34077479-D525D5C4-1A5D-47CF-80F5-84B127E359E1 Q34270868-7CF58388-2296-458E-AA12-5F07F2D4A44B Q34311645-CEBA4506-C06E-4E04-9165-E19EFE630653 Q34906164-E79184BF-A132-41C1-8B11-B1878B5A0486 Q35140097-0B4C9BB1-15D4-476D-B38B-18E31CE6ADB9 Q35143457-9AD202BB-E2FF-41BB-9CCD-F0ADBD50561B Q35524687-4585BA98-57B3-4121-BF71-B09B9B323457 Q35588726-4A68A41C-AB30-4BBF-A191-E137D2E14864 Q35794105-D8872A51-7E0D-41B7-B790-0CCBAD936E5F Q35802202-70BE4913-1E50-415A-92B9-FD2CAE25BADC Q35865095-047955AF-B680-4C7E-B4EA-320805BF804E Q36236504-966A89DE-16C9-4E58-8936-DEEAC2940CC4 Q36471247-227ED84D-18B2-4951-9690-3A7A4F3997B0 Q36876981-B5B9EB0F-D5CA-45DA-9671-E9BADF72420F Q37055805-7FE3F3E4-2112-4E4E-A131-E791564EDFEB Q37075998-3728FA0C-5FC0-4346-95A2-5503D1A1787E Q37245959-E4AED905-95D1-4B00-AC4E-E8CE8D875C4F Q37629847-11C24D0A-1560-4CEA-95D0-7FFC5A3B8990 Q37689179-A639D229-8878-4B4B-9950-BBFC8F745D53 Q37853793-E664F0C9-6164-462F-B24B-CF6C3C167EA8 Q37858415-4755242F-02CE-430A-8D48-88F24CCE2E21 Q37861866-AABDE7DA-8B94-45A2-8B93-BD7DACFB0635 Q37923305-C263E317-2B77-4358-8968-C00429B81741 Q38032083-EA4805C8-A94B-4D65-BB60-739AC4CB7523 Q38033125-6D98C3A9-1275-40B8-B730-8F2880F0F3C2 Q38392246-E650E093-6358-4B38-BE3C-9CC6629012CA Q38416376-287A004A-0D4D-4347-B6FC-C63935745CCC Q38698520-5D29A1D9-2CB9-4D89-93A4-A2B4C35CDD3A Q38733768-AFD858BE-C3DD-4731-942A-C6947B8FC82C Q38866851-FE058E1B-27B8-46FA-983C-75808AD7558D Q39002161-D3CB8764-BF3C-4E35-9523-FE4837839A17 Q39041077-2FD8D872-9CBA-44B6-B13D-FF28799AC5E4 Q40385568-1680301F-768F-4398-B353-3B2DA2646CE2 Q41890316-0ACCF1E2-38EE-4D6B-9E4E-218419DF3CAD

P2860

Imatinib for refractory chronic graft-versus-host disease with fibrotic features.

http://www.wikidata.org/entity/Q46031486

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Imatinib for refractory chronic graft-versus-host disease with fibrotic features.

@en

Imatinib for refractory chronic graft-versus-host disease with fibrotic features.

@nl

type

label

Imatinib for refractory chronic graft-versus-host disease with fibrotic features.

@en

Imatinib for refractory chronic graft-versus-host disease with fibrotic features.

@nl

prefLabel

Imatinib for refractory chronic graft-versus-host disease with fibrotic features.

@en

Imatinib for refractory chronic graft-versus-host disease with fibrotic features.

@nl

P1433

Q46031486-46A060FA-BF8E-43A9-814B-833F96C80831

P1476

Q46031486-57E47FEA-FFA2-4C02-A816-11EB66E746A1

P2093

Q46031486-0A6E9BA2-CE9E-42C3-B50F-0BA905EA4A08

Q46031486-469FCAD4-3D90-4D07-8C5B-4ED73EF3B7B1

Q46031486-57DBEEBD-E227-4535-8886-513A83C86472

Q46031486-6F888FA9-2ECE-412D-98A6-CCAD2FC44583

Q46031486-A6F1D4C9-E877-4100-9063-DA34526A3F3E

Q46031486-A8407073-0083-49E8-8114-C74C2DD520DF

Q46031486-AC77EAC1-5755-4740-BEA6-6274B4C139FE

Q46031486-C27D2D21-4130-498C-AFC9-7C4365A6B5E6

Q46031486-D2215D4D-ECAF-4939-8BB5-4D04A8E98C8D

Q46031486-E4B4A84B-1BAA-4C48-8220-EEED008007C3

P304

Q46031486-EE970AE4-A668-41FD-9A4F-416ED23B851E

P31

Q46031486-06DDD591-1618-446E-9A62-30A38971A265

P356

Q46031486-457141A8-3560-46E8-8B5C-4FE491A7B7ED

P407

Q46031486-48B827D0-160C-4EA9-A681-06398BDFD0C2

P433

Q46031486-B8390173-E13D-407E-9A4C-E79B7BC41A60

P478

Q46031486-0B158B4C-D8A9-450C-92D1-2567588964C4

P50

Q46031486-AA0BC8BC-F253-4D74-80B8-A0A559A31D60

Q46031486-FDC12C38-99D4-4F5F-9578-993CDF5F1AB3

P577

Q46031486-2920B810-2D90-4231-9F32-FEF003524E1D

P5875

Q46031486-0486E803-D160-4CA9-8AEE-5BA1866B21CD

P698

Q46031486-0FE4B9A4-32B7-4486-8AA6-249175160225

P356

BLOOD-2009-02-204156

P1433

P1476

Imatinib for refractory chronic graft-versus-host disease with fibrotic features

@en

P2093

Adele Sanna

http://www.w3.org/2001/XMLSchema#string

Andrea Bacigalupo

http://www.w3.org/2001/XMLSchema#string

Armando Gabrielli

http://www.w3.org/2001/XMLSchema#string

Attilio Olivieri

http://www.w3.org/2001/XMLSchema#string

Franco Locatelli

http://www.w3.org/2001/XMLSchema#string

Guido Gini

http://www.w3.org/2001/XMLSchema#string

Michele Cimminiello

http://www.w3.org/2001/XMLSchema#string

Nicola Mordini

http://www.w3.org/2001/XMLSchema#string

Pietro Leoni

http://www.w3.org/2001/XMLSchema#string

Roberto Raimondi

http://www.w3.org/2001/XMLSchema#string

P304

709-718

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2009-02-204156

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

114

http://www.w3.org/2001/XMLSchema#string

P50

Adriana Balduzzi

P577

2009-04-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24378734

http://www.w3.org/2001/XMLSchema#string

P698

19403889

http://www.w3.org/2001/XMLSchema#string